Motivations for participation in phase 1 drug development trials

这项健康志愿者动机研究是辉瑞国际公司进行的I期药物开发研究的一个子研究。该子研究旨在评估健康参与者在研究中的主要和次要动机，以及参与者决定参与的过程，包括他们对任何风险、福利、补偿和其他因素的考虑，以及这些因素与文化和社会人口变量的关系。数据是在两个可能的时间点通过自我管理的调查收集的，1)在参与初步研究开始时通过同意程序之后，2)在参与研究结束时。数据收集来自3个辉瑞临床研究单位——纽黑文、布鲁塞尔和新加坡，大约1200名参与者完成了第一次调查。数据分析正在进行中。两份手稿正在准备中

This healthy volunteer motivation study is a sub-study of Phase I drug development studies conducted by Pfizer International. The substudy is designed to evaluate the primary and secondary motivations of healthy participants in research studies, as well as the process by which participants decide to participate, including their consideration of any risks, benefits, compensation and other factors, and the relationship of these factors to cultural and sociodemographic variables. Data are collected via self-administered surveys at 2 possible time points, 1) after going through the consent process at the beginning of participation in the primary study, and 2) towards the end of study participation. Data collection is complete from 3 Pfizer Clinical Research Units- New Haven, Brussels, and Singapore, approximately 1200 participants completed the first survey. Data analysis is ongoing. Two manuscripts are in preparation